SCHEMBL4193380

SCHEMBL4193380

Clc1cc2nc(-c3ccc(-c4ccccn4)cn3)[nH]c2cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.63
RAB9A P51151 6/20 0.63
PKM P14618 4/20 0.63
LMNA P02545 3/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
KDM4E B2RXH2 3/20 0.63
MAPT P10636 3/20 0.63
KMT2A Q03164 2/20 0.63
CBFB Q13951 10/20 0.62
METAP2 P50579 7/20 0.59
METAP1 P53582 7/20 0.59
MEN1 O00255 1/20 0.55
HPGD P15428 2/20 0.52
MTOR P42345 1/20 0.52
NPSR1 Q6W5P4 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
TP53 P04637 1/20 0.52
GAA P10253 1/20 0.52
NPY5R Q15761 1/20 0.50
RHEB Q15382 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4189051 0.87 RHEB (0.62) NPC1RAB9APKMLMNASMN1; SMN2
SCHEMBL4183736 0.86 CBFB (0.81) NPC1RAB9APKMLMNASMN1; SMN2
SCHEMBL4177107 0.84 NPC1 (0.54) NPC1RAB9APKMLMNASMN1; SMN2
SCHEMBL4179671 0.80 CBFB (0.56) NPC1RAB9APKMLMNASMN1; SMN2
SCHEMBL4189168 0.78 TRPV1 (0.56) NPC1RAB9APKMLMNASMN1; SMN2
SCHEMBL13223456 0.78 NPC1 (1.00) NPC1RAB9APKMLMNASMN1; SMN2
SCHEMBL13866537 0.78 NPC1 (0.81) NPC1RAB9APKMLMNASMN1; SMN2
SCHEMBL13866538 0.77 NPC1 (0.74) NPC1RAB9APKMLMNASMN1; SMN2
SCHEMBL13866553 0.77 NPC1 (0.74) NPC1RAB9APKMLMNASMN1; SMN2
SCHEMBL17492287 0.76 CBFB (0.64) NPC1RAB9APKMLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US claimed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP claimed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US claimed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same TRPV1, TRPA1, BDKRB2 NPC1 1781/4885RAB9A 2689/4885PKM 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.